



## Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference

January 19, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Compass Therapeutics, Inc.](#), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

The Compass presentation will be live webcast at 10:30 a.m. EST on January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at <https://b-riley-oncology-investor-conference.events.issuereirect.com/signup>. After completion of the event, a replay of the presentation will be publicly available under the "Investors – Events and Presentations" tab on the Compass website at [www.compasstherapeutics.com](http://www.compasstherapeutics.com).

### About Compass Therapeutics

Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company's lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, and is currently being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs.



View source version on [businesswire.com](https://www.businesswire.com/news/home/20210119005222/en/): <https://www.businesswire.com/news/home/20210119005222/en/>

### Media

Compass Therapeutics, Inc.  
Garrett Winslow, Senior Vice President and Head of Legal Affairs  
[media@compasstherapeutics.com](mailto:media@compasstherapeutics.com)  
617-500-8099

Source: Compass Therapeutics, Inc.